NASDAQ:IMDX

Oncocyte Q1 2026 Earnings Results & Report

Oncocyte logo
$1.77 -0.09 (-4.84%)
As of 03:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Oncocyte reported Q1 2026 earnings on May 13, 2026. The company reported EPS of -$0.28, while revenue was $32 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes

Oncocyte EPS Results

Actual EPS
-$0.28
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oncocyte Revenue Results

Actual Revenue
$32 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Oncocyte Q1 2026 Earnings FAQ

Oncocyte (NASDAQ:IMDX) reported earnings of -$0.28 per share for Q1 2026. The report was announced on Wednesday, May 13, 2026.

Oncocyte reported revenue of $32 thousand for Q1 2026.

Oncocyte Earnings Headlines

IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
Insight Molecular Diagnostics Announces Proposed Public Offering
iMDx to Release Third Quarter Results on November 16, 2026
Oncocyte Corporation Registered Shs
See More Oncocyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncocyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncocyte and other key companies, straight to your email.

About Oncocyte

Oncocyte (NASDAQ:IMDX)oration, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection.

The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.

The company’s business has evolved from Oncocyte’s earlier focus on oncology diagnostics, including tests designed to help guide lung cancer treatment. Its current focus is transplant diagnostics, with services primarily directed to the U.S. healthcare market.

View Oncocyte Profile